Most Read Articles
01 Apr 2016
Amiodarone is safe and effective for early junctional ectopic tachycardia prophylaxis in paediatric patients following open heart surgery, based on a study.
Tristan Manalac, 19 May 2018
Taking oral antibiotics appears to increase the risk of nephrolithiasis, according to a recent study. Moreover, the risk seems to be compounded for individuals with recent antibiotic exposure and those who were exposed at a younger age.
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.

Jairia Dela Cruz, 05 Mar 2018
Abaloparatide appears to produce significant increases in the bone mass density (BMD), as well as nominal reductions in fractures, in very elderly women with osteoporosis, with a safety profile similar to that in the overall study population, according to a posthoc analysis of the phase III ACTIVE trial.

Antiepileptic drugs, systemic antibacterials up risk of adverse drug reactions

15 Aug 2017

Use of antiepileptic drugs, a history of adverse drug reactions (ADR) and use of meglumine are all risk factors for ADR in paediatric patients, a new cohort study has shown.

In a cohort of 173 children, with 208 admission and 2,167 prescription data, 109 adverse drug events (ADE) were reported in 52 children. Of these, 12.8 percent (n=14) were classified as definite ADR, 47.7 percent (n=52) were probable, 29.4 percent (n=32) were possible and 10.1 percent (n=11) were classified as doubtful.

An analysis of all definite and probable ADRs showed that gastrointestinal disorders were the most common ADR, comprising 28.8 percent (n=19) of all total cases. This was followed by ADR related to systemic antibacterials (22.7 percent) and general anaesthesia (15.2 percent). The overall incidence rates of definite and probable ADRs were 22.1 and 21.9 percent, respectively.

Multivariate analysis showed that a prior history of ADR (hazard ratio [HR], 2.44; 95 percent CI, 1.19 to 5.00; p=0.01) and an administration of meglumine antimonite (HR, 4.98; 1.21 to 20.54; p=0.02) were significant risk factors for ADRs.

Antiepileptic drugs (HR, 3.84; 1.40 to 10.56; p=0.009) and antibacterials for systemic use (HR, 2.75; 1.08 to 6.98; p=0.03) were also significant risk factors for ADR.

Study participants were recruited from a general paediatric ward of a public teaching hospital in Northeastern Brazil. Only those treated for at least 48 hours were included. Those that were not administered drugs during hospital stay were excluded.

The principal outcome of the study was the occurrence of ADRs. The Naranjo and Hartwig algorithms were used to evaluate causality and severity of ADEs, respectively.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
01 Apr 2016
Amiodarone is safe and effective for early junctional ectopic tachycardia prophylaxis in paediatric patients following open heart surgery, based on a study.
Tristan Manalac, 19 May 2018
Taking oral antibiotics appears to increase the risk of nephrolithiasis, according to a recent study. Moreover, the risk seems to be compounded for individuals with recent antibiotic exposure and those who were exposed at a younger age.
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.

Jairia Dela Cruz, 05 Mar 2018
Abaloparatide appears to produce significant increases in the bone mass density (BMD), as well as nominal reductions in fractures, in very elderly women with osteoporosis, with a safety profile similar to that in the overall study population, according to a posthoc analysis of the phase III ACTIVE trial.